By scrutinizing the connections between CYP1A2 polymorphisms and BLCA risk, this research endeavors to contribute to the existing understanding of the genetic determinants influencing susceptibility to bladder cancer, potentially informing the development of targeted strategies for prevention and treatment of BLCA. The gene discussed is CYP1A2; the disease is urinary bladder cancer.